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ABSTRACT: Background:  Using nicotine replacement therapy (NRT) while
still smoking in the lead up to quitting could enhance success at quitting, one of
the most cost-effective means of improving health, but little is known about its
acceptability and tolerability. Aim: To test the acceptability and tolerability of
using  NRT  while  smoking  for  two  weeks  before  quitting,  to  inform  a
randomised  controlled  trial  of  pre-quitting  NRT  versus  usual  NRT-based
quitting practice.  Methods: Prospective pragmatic uncontrolled clinic-based
pilot study in which 14 adult smokers recruited from a smoking cessation clinic
were prescribed nicotine patches or gum with follow up for two weeks.  Data
were collected on participants’ concerns about smoking while using NRT,
importance of quitting, urges to smoke, smoking behaviour, previous NRT use
and the length of the pre-quitting period.  Urine tests were collected weekly for
cotinine, and participants recorded smoking activity and noted experiences and
changes in their health in diaries. Results:  Only 21% of 14 participants
expressed concerns about using NRT while smoking. All of the nine followed
up used it as recommended, 56% of these reporting no unpleasant symptoms.
Median urine cotinine levels declined over the two weeks.   Urges to smoke
averaged 1.8 on a 4-point scale.   All participants decreased the number of
cigarettes per day.  Diary records showed wide variation in smoking and NRT
use, with an increased sense of control and determination to quit. Conclusions:
Smokers using pre-quitting NRT over two weeks appeared to titrate nicotine
levels and symptoms of toxicity were uncommon and of low intensity.
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INTRODUCTION
Quitting  smoking  using  nicotine
replacement therapy (NRT) is one of the
most cost-effective means of reducing
risk and improving current and future
health, yet sustained quitting rates are
still far from ideal.
1  New approaches are
needed to enhance the effectiveness of
NRT.   NRT  was  licensed  to  manage
tobacco  withdrawal  symptoms  rather
than to reduce dependence on cigarette
nicotine  and  so  in  most  Quit
programmes NRT is used from the quit
date, not before.   Two studies suggest
positive effects from introducing NRT
before the quit date.   In a trial of 332
smokers  Herrera  et  al 
2  found  that
allowing  participants  to  familiarize
themselves  with  NRT  gum  a  week36 Bullen C, Whittaker R, Walker N, Wallace-Bell M
before quit day increased abstinence at 6
weeks,  though  not  significantly.
Schuurmans  et  al 
3  randomized  200
smokers  to  receive  active  or  placebo
patches two weeks prior to quitting, and
showed  a  near  doubling  in  sustained
abstinence  at  6  months  in  the  active
compared with the control group (22%
versus 12%, p=0.03).
Prior  to  embarking  on  a  large
randomised  controlled  trial  of  pre-
quitting NRT versus usual practice on
quit rates at six months, we undertook a
small  pilot  study  involving  adult
smokers who attended a cessation clinic.
We  aimed  to  investigate  the
acceptability, toxicity and tolerability of
NRT while still smoking, for two weeks
prior to the nominated quit day.
METHODS
Participants: Adult smokers of at least
10 cigarettes per day who wanted to quit
within the next few weeks were recruited
into this prospective, uncontrolled non-
experimental study between February-
March  2005  at  a  university  cessation
clinic in Christchurch, New Zealand in
response  to  a  local  newspaper
advertisement.   People  with  unstable
medical  conditions,  or  who  were
pregnant,  breastfeeding  or  on
psychotropic medication, were excluded.
The study was approved by the local
research  ethics  committee  and  all
participants provided written informed
consent.
Treatment:  Participants received two
weeks supply of NRT, either as patches
or gum in doses appropriate to their level
of  dependence,  as  determined  by
discussion  between  client  and  a
cessation therapist (MW-B), to use while
still smoking ad libitum for two weeks
prior  to  a  nominated  Quit  Day.
Instructions were given to participants
that they could continue smoking as they
wished over this period. Eight weeks of
subsidized  NRT  treatment  combined
with  support  telephone  calls  then
followed Quit Day, in line with standard
cessation practice in New Zealand.   In
this pilot study only the two week pre-
quit period was studied.
Measures:  Brief  questionnaires  were
administered at enrolment and one week
later by one of the investigators (MW-B)
to collect demographic (enrolment only)
and  smoking-related  data  (including
smoking history, cigarette consumption,
measure  of  nicotine  dependence  and
previous NRT use). Participants rated
urges  to  smoke  on  a  5-point  scale
(0=none to 4=severe), and importance of
quitting on a scale of 1 (no importance)
to  9  (very  important).  They  provided
urine  samples  for  cotinine  testing  at
enrolment,  and  at  seven  and  fourteen
days  post-enrolment  (Quit  Day).
Cotinine  was  measured  at  a  regional
hospital laboratory using capillary gas
chromatography and nitrogen selective
detection.  Diaries  were  given  to
participants at enrolment to record daily
smoking  consumption,  NRT  use  and
note any toxicity-related symptoms and
other relevant experiences. On Quit Day,
diaries  were  collected,  final  urine
cotinine samples taken, a supply of NRT
provided  for  the  next  4  weeks  and
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RESULTS
Fourteen  of  the  fifteen  (93%)  people
responding  to  the  newspaper
advertisement met the study inclusion
criteria,  67%  of  them  female,  with  a
median age of 44 yrs (range 18-70 yrs)
and  all  but  one  of  European  New
Zealander  ethnicity.   Participants
smoked  on  average  21  (range  10-35)
cigarettes  per  day  (cpd).  All  were
interested in finding new ways to quit,
and  rated  quitting  highly  (mean  8.4,
range 7 – 9).  All participants had used
NRT before, nine (64%) using patches,
two (14%) gum, two (14%) both patch
and  gum;  one  did  not  answer  the
question.  Most (71%) had no concerns
about using NRT while they were still
smoking.   Of those with concerns, two
were  worried  about  overdose  and  the
other about feeling light-headed.  Eleven
(79%)  participants  kept  diaries  and
completed the follow-up questionnaire
Pre-quitting  NRT  use:  Eleven
participants  (79%)  used  NRT  as
recommended; three were unresponsive
to follow up calls. Eight (64%) received
15mg/16hr  NRT  patch,  two  (14%)
10mg/16hr NRT patch, three (21%) 2mg
NRT  gum,  and  one  4mg  NRT  gum.
Excerpts from participants’ diaries give
insight  into  their  experiences  as  they
embarked  on  the  study.   Several
participants were optimistic about their
chances of success:
“I have more success integrating and
maintaining new habits when introduced
gradually rather than drastic changes”
(Start of Day 1, usually smoked 14 cpd)
“Patch on at 7.00am, coffee and felt that
I  shouldn’t  smoke.”  (Start  of  Day  1,
usually smoked >30 cpd)
Gum  was  uniformly  regarded  as
unpleasant to taste whereas patches were
well-tolerated.  When asked on Day 14
whether  the  two  week  period  of  pre-
quitting NRT was adequate to prepare
for quitting, 55% preferred at least 3-4
weeks,  three  felt  two  weeks  was  just
right while two recommended a shorter
period.
Cigarette consumption and urges to
smoke:   Considerable  day-to-day
variation  in  smoking  patterns  was
evident.   Smoking  reduced  by  an
average of 4 cpd (range 2-10) in the 11
participants  for  whom  data  were
available.   None  stopped  smoking
completely.   Urges to smoke over the
pre-quit  period  were  rated  mild-
moderate, mean score 1.7/4 (range 0-3).
Further diary excerpts shed light on the
participant’s experiences.  At the end of
the first day, one participant commented
on the power of habit despite low level
of cravings:
“Didn’t  often  feel  like  smoking,  but
habituated …after lunch…after work”
(end of Day 1, usually smoked 20/day)
“Morning craving not so pronounced –
cigarettes are beginning to taste awful”
(Day 5, usually smoked >2 cpd)
“Three smokes and one gum at 3.30 pm
–feeling  confident  about  working
towards  quit  day”  (Day  5,  usually
smoked 10 cpd)
“I have noticed I am not so preoccupied
with making sure I have cigarettes with
me  when  leaving  the  car”  (Day  7,
usually smoked 15 cpd)
“For the first time in years did not have
cigarette first thing.   Felt better.   Had38 Bullen C, Whittaker R, Walker N, Wallace-Bell M
three cigarettes later on and felt lousy”
(Day 7, usually smoked 15 cpd)
“15 cigarettes today.  Started buying 20
packs instead of 30.” (Day13, usually
smoked 17-20 cpd)
“Patch  on  when  I  awoke;  had  two
cigarettes in the morning, two at midday
and  one  in  the  afternoon.  Felt  fine
today” (Day 14, usually smoked 30 cpd)
Symptoms  of  nicotine  toxicity:
Participants  reported  few  unpleasant
feelings  related  to  use  of  NRT  while
smoking.  Only  four  reported
experiencing symptoms, including mild
nausea,  low-grade  headaches,  sleep
disturbance  and  dizziness,  and  were
most likely due to high nicotine levels
rather than withdrawal.
4  Urine cotinine
levels  converged  over  the  pre-quit
period,  from  a  median  level  of  1515
(range 470-6410) to 1325 (range 470-
5210)  at  two  weeks.  The  subjective
experiences documented in the diaries
bore no correlation to nicotine levels or
with the type or dose of NRT.
“Initially  felt  ‘racy’  but  [patch]
definitely  has  helped,  inhaling  less
deeply …able to delay several hours”
(Day 14, usually smoked 20 cpd)
DISCUSSION
Despite being small and uncontrolled,
this study nevertheless provides some
useful insights into concomitant smoking
and NRT use prior to quitting. First, the
findings  align  with  those  from  other
studies showing NRT use while smoking
to  be  safe.
5   Few   participants
experienced  symptoms  that  could  be
attributed  to  toxicity,  and  these  were
relatively mild in nature.  Urine cotinine
levels  were  not  at  a  level  to  cause
concern.
A  second  and  related  finding  is  that
urges  to  smoke  were  only  mild  to
moderate in strength, and therefore, we
suggest, likely to enable a more positive
experience for smokers planning to quit
compared  to  the  usually  abrupt
transition.  Past positive experiences are
the  most  influential  source  of  self-
efficacy, which is important in making
behavior changes.
6   Also,  easing  the
trauma  of  transition  around  the  quit
period  has  been  shown  to  be  a
significant factor in long term quitting
success.
7
Thirdly,  all  participants  reduced
smoking during the pre-quit phase, two
thirds by more than 5 cpd, in line with
the finding from a review by Fagerstrom
and  Hughes  of  eleven  studies  with
concomitant smoking and NRT use in
which the number of cpd declined by
50%.
5    We  did  not  measure  carbon
monoxide (CO) in this study but others
have found a reduction of 30% in this
context, suggesting that compensatory
smoking is not a significant issue.
5   It
has been proposed that smokers regulate
their  smoking  behavior  to  obtain  a
constant characteristic nicotine level, for
example  by   increasing  smoke  intake
when the nicotine supply is reduced or
decreasing  smoke  intake  when  extra
nicotine is received from another route.
8
However,  mixed  results  have  been
obtained  when  this  model  has  been
tested. Foulds et al 
9 for example, in a
randomized double blind crossover trial
of nicotine and placebo patches with ad
libitum smoking, reported no fall in cpd
but a 14% drop in CO together with less
satisfaction from cigarettes and fewer
and weaker urges to smoke. Our study,Pre-quitting nicotine replacement therapy:  Findings from a pilot study 39
however, supports the notion of down-
regulation of nicotine intake.   Studies
examining the effect of nicotine gum on
ad-lib smoking have found an inhibitory
effect 
10 but this may be dose-related.
11
Using nicotine gum may of itself result
in a reduction in cigarette smoke intake
simply because one cannot smoke while
chewing gum. The use of intravenous
nicotine infusion avoids this problem
12
but  the  results  are  not  clear-cut  as
laboratory-based environments in which
such studies are conducted lack the usual
cues to smoking.
Fourthly, the two-week pre-quit period
appears to a reasonably acceptable pre-
quitting  period,  and  likely  to  be
sufficient for effectiveness, based on the
experience of Schuurmans et al.
3
Finally, several themes emerged from
the analysis of participant’s diaries that
shed light on possible mechanisms for
any  effect,  if  indeed  one  exists:  an
increasing sense of personal control over
smoking; and a reduction in the stress
associated with changing smoking and
cigarette purchasing behavior compared
with previous quit attempts.
CONCLUSIONS
Our findings suggest that a short period
of  around  two  weeks  concomitant
smoking and NRT patches or gum at
normally prescribed doses may maintain
nicotine  at  high  but  safe  and  well-
tolerated levels sufficient to minimize
cravings.  This may facilitate a gradual
reduction  in  smoking  through  down-
regulation.   We hypothesize that this,
together  with  a  growing  sense  of
personal  control  over  smoking
behaviors,  may  facilitate  a  more
successful  and  sustained  transition  to
quitting  than  the  usual  practice  of
suddenly stopping the main source of
nicotine (i.e. cigarettes) on Quit Day.  A
large  randomized  trial  is  planned  to
address this key question.  The trial will
also  enquire  in  detail  about  smoking
activity and NRT use over the pre-quit
and  immediate  post-quit  period  to
further  illuminate  the  various
mechanisms that underpin the changes
and experiences of smokers undertaking
this approach.
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